Next Article in Journal
In Vivo Efficacy of Artesunate/Sulphadoxine-Pyrimethamine versus Artesunate/Amodiaquine in the Treatment of Uncomplicated P. falciparium Malaria in Children around the Slope of Mount Cameroon: A Randomized Controlled Trial
Next Article in Special Issue
Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
Previous Article in Journal
In Vitro Synergistic Enhancement of Newcastle Disease Virus to 5-Fluorouracil Cytotoxicity against Tumor Cells
 
 
Review

Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy

1
School of Molecular Biosciences, Washington State University, Pullman, WA 99164, USA
2
Pharmaceutical Sciences, College of Pharmacy, Washington State University Spokane, Spokane, WA 99202, USA
*
Author to whom correspondence should be addressed.
Academic Editor: N. Manjunath
Biomedicines 2016, 4(1), 4; https://doi.org/10.3390/biomedicines4010004
Received: 9 October 2015 / Revised: 26 January 2016 / Accepted: 28 January 2016 / Published: 2 February 2016
(This article belongs to the Special Issue Gene Therapy Strategies for HIV/AIDS)
Retroviral vector gene therapy is a promising approach to treating HIV-1. However, integrated vectors are mutagens with the potential to dysregulate nearby genes and cause severe adverse side effects. Leukemia has already been a documented severe adverse event in gene therapy clinical trials for the treatment of primary immunodeficiencies. These side effects will need to be reduced or avoided if retroviral vectors are to be used clinically for HIV-1 treatment. The addition of chromatin insulators to retroviral vectors is a potential strategy for reducing adverse side effects. Insulators have already been effectively used in retroviral vectors to reduce genotoxicity in pre-clinical studies. Here, we will review how insulators function, genotoxicity in gene therapy clinical trials, the design of insulated retroviral vectors, promising results from insulated retroviral vector studies, and considerations for the development of insulated retroviral treatment vectors for HIV-1 gene therapy. View Full-Text
Keywords: retroviral vector; insulator; genotoxicity; insertional mutagenesis; anti-HIV; gene therapy; clinical trial retroviral vector; insulator; genotoxicity; insertional mutagenesis; anti-HIV; gene therapy; clinical trial
Show Figures

Graphical abstract

MDPI and ACS Style

Browning, D.L.; Trobridge, G.D. Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy. Biomedicines 2016, 4, 4. https://doi.org/10.3390/biomedicines4010004

AMA Style

Browning DL, Trobridge GD. Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy. Biomedicines. 2016; 4(1):4. https://doi.org/10.3390/biomedicines4010004

Chicago/Turabian Style

Browning, Diana L., and Grant D. Trobridge. 2016. "Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy" Biomedicines 4, no. 1: 4. https://doi.org/10.3390/biomedicines4010004

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop